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A B S T R A C T
Purpose: Zonisamide is licensed for adjunctive therapy for partial-onset seizures with or without
secondary generalisation in patients 6 years and older and as monotherapy for the treatment of partial
seizures in adult patients with newly diagnosed epilepsy, and shows a favourable pharmacokinetic
proﬁle with low interaction potential with other drugs. The aim of the present study was to gather real-
life data on retention and modalities of zonisamide use when administered as only add-on treatment to a
current AED monotherapy in adult patients with partial-onset seizures.
Methods: This multicenter observational study was performed in 4 European countries and comprised
three visits: baseline, and after 3 and 6 months. Data on patients’ retention, reported efﬁcacy, tolerability
and safety, and quality of life was collected. Of 100 included patients, 93 could be evaluated.
Results: After 6 months, the retention rate of zonisamide add-on therapy was 82.8%. At this time, a
reduction of seizure frequency of at least 50% was observed in 79.7% of patients, with 43.6% reporting
seizure freedom over the last 3 months of the study period. Adverse events were reported by 19.4% of
patients, with fatigue, agitation, dizziness, and headache being most frequent. Approximately 25% of
patients were older than 60 years, many of whom suffered from late-onset epilepsy. Compared to
younger patients, these patients showed considerable differences with regard to their antiepileptic drug
regimen at baseline, and slightly higher responder and retention rates at 6 months.
Conclusions: Despite limitations due to the non-interventional open-label design and the low sample
size, the results show that zonisamide as only add-on therapy is well retained, indicating effectiveness in
the majority of patients under real-life conditions.
 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.
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Focal epilepsy comprises simple and complex partial as well as
secondarily generalized seizures and represents the most common
form of epilepsy [1]. Epidemiological studies show that, akin to
early childhood, the incidence of epilepsy peaks in the elderly
population [2]. For most patients, epilepsy represents a life-long* Corresponding author at: Epilepsy Center Dept. of Neurology, University
Hospital Erlangen, Schwabachanlage 6, 91054 Erlangen, Germany.
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1059-1311/ 2015 Published by Elsevier Ltd on behalf of British Epilepsy Association.condition, and more than 50 million people are affected worldwide
[3]. Monotherapy with antiepileptic drugs (AEDs) is the ﬁrst-line
treatment for partial-onset seizures (POS), however, more than one
third of the patients show inadequate seizure control under
monotherapy and thus require AED-combination regimens [4–
6]. In addition, treatment dissatisfaction, low compliance and
adherence are major reasons for sustained insufﬁcient seizure
control [7,8]. Adverse events, due to poor AED tolerability proﬁles
or inacceptable toxicities due to drug–drug interactions of AEDs
with combination partners, as well as other concomitant medica-
tions [9], are among the main determinants of low treatment
adherence and impaired quality of life (QoL). This highlights the
need for additional add-on therapy options that will beneﬁt these
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adherence, lack of interactions with other medications, and QoL.
Zonisamide was introduced in Europe in 2005 for adjunctive
therapy of POS, with or without secondary generalisation. It is
currently licensed as adjunctive therapy for POS in patients 6 years
and older and as monotherapy for the treatment of POS in adult
patients with newly diagnosed epilepsy. The antiepileptic mecha-
nisms of action of ZNS, while still not completely understood, are
thought to be mediated through its action on voltage-sensitive
sodium and calcium channels, as well as through modulation of
GABAergic signaling [10].
The efﬁcacy and safety of ZNS as adjunctive therapy for the
treatment of refractory POS have been investigated in randomized
controlled trial settings in the United States and Europe. The
duration of these trials was up to 36 weeks with active ZNS
treatment dosing either once or twice daily. In total, 845 patients
with treatment-refractory POS with or without secondary
generalisation, were randomized in these trials, and the ﬁndings
demonstrated that ZNS was generally well tolerated and efﬁca-
cious as adjunctive therapy in these patients [11–14], with a
recommended dose range for maintenance therapy between
300 and 500 mg/d. However, patients in controlled clinical trial
settings are usually suffering from more severe and treatment-
refractory disease, and interventional studies do not allow for
individualized dosing regimens. Thus, the aim of the present
observational study ZOOM was to gain a broader clinical real-life
practice insight on the use and retention of ZNS add-on therapy at
earlier treatment stages in adult patients, and to investigate
potential differential effects of ZNS in combination with different
baseline AEDs.
2. Patients and methods
This open-label, observational study with zonisamide as add-on
treatment in adult patients with POS, was performed in 38 centers
across 4 European countries between 28 March 2012 and 15 July
2013. The majority of centers were located in Germany; Norway,
Denmark and Sweden each contributed one site. The trial was
registered in www.clinicaltrials.gov (NCT01830868), and had been
subject to regulatory and ethical approval in all countries involved.
Study participation was offered to adult patients with POS
whose epilepsy was insufﬁciently controlled with a current
antiepileptic monotherapy, and thus required addition of ZNS to
their antiepileptic regimen according to the physicians’ clinical
judgment. No further selection criteria with regard to patients’
treatment history were applied.
The patients’ seizure situation was to be assessed based on
patient diaries, other written information sources, or patient
interviews. The decision to prescribe ZNS was made by the
physicians independently of their decision to include the patients
into the study. Treatment was to be applied as per recommenda-
tion in the ZNS Summary of Product Characteristics (SmPC).
Patients undergoing off-label therapy with ZNS, patients who
had started ZNS treatment more than 2 weeks prior to enrollment,
or who concomitantly suffered from severe psychiatric disorders,
were excluded from participation.
Upon the patient signing informed consent, baseline data on
demographics, medical history, previous antiepileptic therapy,
reason for ZNS prescription and concomitant medication and
diseases were collected, and the physicians were to record the
planned titration schedule for ZNS add-on therapy. In addition,
patients were asked to complete a health related quality of life
questionnaire (Quality of Life in Epilepsy Inventory-10; QOLIE-
10)[15]; the QOLIE-10 was applied for a subset of sites where it was
used in routine clinical practice and was available and validated in
local language. The QOLIE-10 consists of 10 questions aboutaspects of health and daily activities that could potentially be
negatively affected by epilepsy and its treatment. Questions refer
to the previous 4 weeks. Lower values of the score reﬂect better
quality of life [15].
Intermediate assessment was expected to be performed at
about 3 months, the ﬁnal assessment at about 6 months after the
baseline visit. However, due to the non-interventional character of
the study, no exact visit windows could be deﬁned, and the visit
schedule was up to the physician’s discretion.
The primary endpoint was the retention rate of ZNS after
6 months from baseline. Secondary endpoints encompassed
tolerability, patient-reported efﬁcacy over 3 month intervals
(again based on patient diaries, other written information, or
patient interviews), ZNS and concomitant AED dosage, and QOLIE-
10 score. In addition, subgroup analysis of ZNS retention rate and
reported efﬁcacy was performed according to age, class of
concomitant AED medication, as well as the number of previously
discontinued AED regimens [6,16]).
2.1. Statistical analysis
Descriptive statistical analyses were performed for all patients
who had completed informed consent, received at least one dose of
ZNS, and had at least one post-dose safety assessment (evaluable
patients). Quantitative variables were analyzed by means of basic
statistical parameters, while qualitative and ordinal scaled variables
were presented by means of absolute and relative frequency
distributions. Relative frequencies were based on the number of
available data, i.e. excluding missing data. No imputation methods
of missing values were applied to the data. Additionally, two sided
95%-conﬁdence intervals (CI) were calculated for the retention rates
over 3 and over 6 months, respectively. For subgroup analyses,
patients were classiﬁed according to gender, age (60 years, >60
years) and the number of discontinued AED regimens within the
last 5 years prior to baseline. Patients were further classiﬁed with
respect to their concomitant baseline AED into the following
4 subgroups: carbamazepine or oxcarbazepine (CBZ + OXC), leve-
tiracetam (LEV), lamotrigine (LTG) and valproate (VPA). Seven
patients taking other than the above AEDs were subsumed under a
‘‘Various’’ class, and are not shown in the present manuscript.
Changes in QOLIE-10 scores were also analyzed in dependency of the
patients’ seizure outcome at the 6-months visit by means of
ANCOVA, with baseline QOLIE-10 level as covariate. Due to the
exploratory nature of this analysis, no correction of multiple testing
was performed.
All analyses were performed with the SAS1 package, version
9.2 (SAS Institute, Cray, NC, USA).
3. Results
3.1. Baseline description of patient population
Initially, it was planned to include 700 patients in the study.
However, due to slow recruiting, this number of patients could not
be achieved. Recruitment was stopped after the inclusion of the
ﬁrst 100 patients, of which 93 were evaluable, i.e. they had
received at least one dose of ZNS, and had at least one post-dose
safety assessment. Of these, 93 attended the baseline and 3-month
follow-up visits, and 81 the 6-month follow-up visit. The mean
duration of study participation was 181.8 days (range 19–337
days); mean duration until attending the 3-months visit was
93.9 days, and 189.2 days until attending the 6-months visit.
The gender distribution was balanced (46.2% male), the median
age was 46 years (range 19–87); 25.8% of the patients were older
than 60 years. The mean time since the initial diagnosis of epilepsy
with POS was 13.4 years for all patients, and this time was shorter
Table 1
Seizure frequency over 3 months prior to baseline.
Simple
partial
seizures
Complex
partial
seizures
Secondarily
generalised
seizures
Total
number of
seizures
N 36 59 47 93
Missing 57 34 46 0
Mean 38.3 8.2 2.1 21.1
SD 106.6 11.1 2.7 68.1
Minimum 0 0 0 0
Median 4 6 1 6
Maximum 600 60 12 600
N describes all patients for whom an entry was provided by the physician (i.e. if
entry was 0 the patient was counted), while if no data were entered in a given
seizure category, the patient was considered missing for this analysis.
H. Hamer et al. / Seizure 34 (2016) 66–7368for patients who were older than 60 years (median: 7.5 years) than
for younger patients (median: 10.6 years). The seizure situation
over 3 months prior to baseline is shown in Table 1 and
Fig. 1. Almost one third (29.1%) of patients suffered from more
than one seizure type (Fig. 1B). Four patients were documented as
free of seizures at baseline.
For 55 patients (59.1%), there was a documentation of at least
one AED being discontinued during the last 5 years before0 20 40 60
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
80 10
0
20
0
60
0
Number  of  seizure s of any  type
N
um
be
r o
f p
at
ie
nt
s 
w
ith
 s
ei
zu
re
s
only
sim
ple
only
com
plex
only
sec
ond
arily
gen
eral
ised
sim
ple/
com
plex
sim
ple/
gen
eral
ised
com
plex
/gen
eral
ised
sim
ple/
com
plex
/gen
eral
ised non
e
0
10
20
30
40
pa
tie
nt
s 
(%
)
A
B
Fig. 1. Seizure situation over a period of 3 months prior to baseline. (A) Bars
represent the number of patients with a given number of seizures of any type
(simple partial or complex partial or secondarily generalised). (B) Proportions of
patients with either simple partial, complex partial or secondarily generalised
seizures or combinations thereof. Four patients were seizure free over a period of
3 months prior to baseline (category ‘‘none’’).enrolment into the study; of these, 26 patients (28.0%) had exactly
one, 16 patients (17.2%) had two, and 13 patients (14.0%) had 3 or
more discontinued AED regimens documented. Only 9 out of
24 patients (37.5%) who were older than 60 years had any
documented discontinued AED during the last 5 years. In contrast,
this was the case for 66.7% (46 out of 69 patients) of the younger
patients.
3.2. Dosing of ZNS as add-on therapy
The main reason for prescribing ZNS add-on therapy was the
lack of efﬁcacy of AED monotherapy (90.3%), followed by adverse
events caused by previous AED treatment (10.8%). The median
planned ﬁrst target dose of ZNS was 200 mg/d (range: 50–400 mg/
d), without marked differences between age groups. In 83.9% of the
patients, the target dose was achieved after a mean of 33.2 days
(SD  27.5 days), and within a mean of 2.6 titration steps
(SD  1.5 steps; range: 1–7 steps). The number of titration steps
was not affected by patients’ age. The mean maximal dose reached
after titration was 229.0 mg/d (116.9 mg); the minimal post-
titration dose reported was 25 mg/d. Dose changes after achieving the
target dose were reported for 17 patients (18.3%): for 9 patients, a
dose reduction was documented, and for 8 a dose increase. The mean
number of dose changes was 2.2  1.6 (range: 1–6 dose changes) (not
shown). Subgroup analysis according to age showed a lower mean
post-titration ZNS dosage in patients older than 60 years (mean  SD:
185.3  47.7 mg/d), compared to younger patients (mean  SD:
229.2  111.0 mg/d).
3.3. Antiepileptic drug medication at baseline
All patients were to receive concomitant AED medication
licensed for monotherapy at baseline (Fig. 2). The vast majority of
patients (n = 85, 91.4%) received only one concomitant AED at
baseline, as deﬁned by inclusion criteria; for 7 patients (7.5%), two
concomitant AEDs, and for one patient (1.1%), 5 AED were
documented.
Five patients were prescribed lacosamide as concomitant AED
during the study, which is currently not licensed for monotherapy
of POS. The majority of patients (66.7%) had no documented change
in their concomitant AED medication during the course of the
study. For 16.1%, a withdrawal and/or dose change of a concomitant
AED was documented, and for 8.6% a novel prescription of an AED.
Considerable differences between younger (60 years) and olderLe
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Fig. 2. Concomitant AED medication at baseline by age groups. Patients had to have
documentation of at least one concomitant AED licensed for monotherapy at
baseline in order to be evaluable; multiple entries were possible. Only the four most
frequently reported drugs/drug classes are shown; AED reported in <5% of patients
are not shown. The subgroup carboxamide derivatives includes patients taking
carbamazepine or oxcarbazepine.
H. Hamer et al. / Seizure 34 (2016) 66–73 69(>60 years) patients regarding the intake of concomitant AED
medication was observed for levetiracetam (more frequent in older
patients), valproate (less frequent in older patients) and oxcarba-
zepine (no prescription in older patients).
3.4. Retention of ZNS add-on therapy
For the total population, the 6 month retention rate of ZNS add-
on therapy was 82.8% (95%-CI: 73.6–89.8%). The retention rate at
3 months was higher with 91.4% (95%-CI: 83.8-96.2%). Subgroup
analysis of the 6-month retention rate by age showed a slightly
higher retention in patients older than 60 years: 87.5% (95%-CI:
[67.6%, 97.3%]) vs. 81.2% (95%-CI: [69.9%, 89.6%]) for patients 60
years (Fig. 3A). The 6-month retention rate varied for the 4 most
frequently prescribed baseline AED-subgroups between 78.6% in
the levetiracetam group (95%-CI: [59.0%, 91.7%]), 78.9% (95%-CI:
[54.4%, 93.9%]) for valproate, 88.0% (95%-CI: [68.8%, 97.5%]) for
patients taking carboxamide derivatives up to 92.9% (95%-CI:
[66.1%, 99.8%]) in the lamotrigine group (Fig. 3B).Fig. 3. Kaplan Meier analysis of retention of ZNS add-on therapy. (A) Subgrouping by patie
were those who left the study, or were lost to follow-up.3.5. Reported efﬁcacy
At 3 months, 39.3% of the patients reported to be seizure free,
and seizure freedom rate at 6 months was 43.6%. The responder
rate (proportion of patients with a reduction of seizure frequency
of at least 50%) was 78.8% at 3 months, and 79.7% at 6 months
(Fig. 4A). For all seizure types, a reduction of seizure frequency was
observed throughout the study (Fig. 4B); the median of total
seizure frequency dropped from 6.0 at baseline (see also Table 1) to
1.0 at both, the 3- and the 6-months visits.
Correspondingly, overall seizure outcome rated by the physi-
cians at the 6-month follow-up visit was ‘‘good’’ or ‘‘very good’’ in
77.6% of the patients.
While the responder rate at 3 months was not affected by
patients’ age, the rate was higher at 6 months in patients older than
60 years than in the younger group (90.0% vs. 75.9%) (not shown).
Responder rates varied considerably with respect to the
number of previously discontinued AED regimens. After 6 months,
the highest responder rate was observed for patients without anynts’ age at baseline. (B) Subgrouping by baseline AED medication. Censored patients
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Fig. 4. Reported efﬁcacy at 3- and 6-month follow-up visits. (A) Responder rate (50% reduction of seizure frequency compared to baseline, black bars) and seizure freedom,
sorted by seizure type (white bars: total number of seizures; light gray: simple partial seizures; medium gray: complex partial seizures; dark gray: secondarily generalised
seizures). (B) Median and inter quartile range (IQR, 25% and 75% quantiles) for the number of seizures of given type or all seizures (black triangles) throughout the study. The
baseline data correspond to data presented in Table 1. For seizure categories, only patients with a corresponding entry were considered for the calculation, i.e. if no entry was
provided by the physician for a given seizure category, the patient was considered missing and was not considered for calculation of mean seizure number. For both A and B,
the number of seizures during the periods spanning 3 month intervals before each visit are given.
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with 3 AEDs (66.7%). Responder rates for patients with one or two
previously discontinued AEDs were 75.0% and 80.0%, respectively.
3.6. Quality of life
The QOLIE-10 was completed at baseline by 74 patients, at the
3-month visit by 73 patients, and at the 6-month visit by
65 patients. The mean value of the score declined from 2.8 at
baseline to 2.4 at 3 months and to 2.0 at the 6-month visit, with
lower values representing better QoL [15] (Fig. 5A).
While age >60 years and female gender were associated with
slightly worse baseline health-related quality of life, after
6 months, QOLIE-10 scores did not differ between the age and
gender subgroups (not shown). Similarly, no major inﬂuence on
QOLIE-10 scores was observed in subgroup analyses by baseline
AED and number of previously discontinued AED regimens (not
shown). The patients’ seizure situation at the ﬁnal visit (after
6 months) had a signiﬁcant impact on the improvement of QoL
throughout the study. Patients who had become seizure-free after
6 months showed a signiﬁcantly lower QOLIE-10 score at 6 months
than patients for whom the seizure frequency reduction was lessthan 50% (Fig. 5B). Statistical signiﬁcance was determined by
means of ANCOVA, with baseline QOLIE-10 level as covariate.
3.7. Tolerability
The physicians’ overall appraisal of the tolerability of ZNS add-
on therapy was in most cases ‘‘very good’’ (63.1%) or ‘‘good’’ (31.0%).
For 2 patients, the tolerability of ZNS was assessed as ‘‘poor’’—each
of these two patients had a documented adverse event (aggression;
tremor and nausea) which was considered related to ZNS
treatment; for 9 patients, the respective information was missing.
The majority (96.1%) of patients in whom ZNS treatment was not
discontinued during the study wished to continue treatment with
ZNS beyond the study.
3.8. Adverse events
Overall, 31 adverse events (AEs) were reported in 18 patients
(19.4%), thereof 5 patients (5.4%) with at least one serious AE.
23 adverse drug reactions (ADRs), deﬁned as an AE with a causal
relationship to ZNS, were reported in 14 patients (15.1%). For
3 patients (3.2%), an AE was the reason for withdrawal of ZNS
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Fig. 5. Quality of life assessed by means of the QOLIE-10 questionnaire, with lower values representing better QoL. (A) Course of QOLIE-10 score throughout the study for the
entire study population (circles), or stratiﬁed according to the seizure situation at month 6 (squares: seizure free patients; white triangles: patients with seizure frequency
reduction of 50–99% compared to baseline; black triangles: patients with seizure frequency reduction <50% compared to baseline). (B) Change of QOLIE-10 score between
baseline and month 3 or month 6 visit, respectively stratiﬁed according to seizure situation at month 6 (see A). Statistical signiﬁcance was determined by means of ANCOVA,
with baseline QOLIE-10 level as covariate. In A and B, mean and SD are shown. QOLIE-10 was only completed by a subset of patients (baseline: N = 74, 3-month follow-up:
N = 73, 6-month follow-up: N = 65). Mean and SD are depicted.
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tremor and nausea; in 5 patients (5.3%), ZNS was discontinued
during the study due to lack of efﬁcacy.
The most frequent AEs with respect to System Organ Class
(SOC) were nervous system disorders (8 patients, 8.6%) and
psychiatric disorders (6 patients, 6.5%). For the latter 6 patients, the
following 7 AEs were reported: impulsive behavior (n = 1),
depression (n = 1), agitation (n = 2), dyssomnia (n = 1), psychotic
disorder (n = 1), and aggression (n = 1).
The most frequently reported preferred terms (PTs) of AEs were
fatigue (3 patients, 3.2%), agitation, dizziness and headache (each
2 patients, 2.2%). Bodyweight loss of 2 kg was reported as an
adverse event in one patient.
4. Discussion
Suffering from epilepsy has a major impact on quality of life,
and the treatment and long-term control of epilepsy are
challenging [7]. Although the majority of newly diagnosed patients
will respond to initial antiepileptic therapy and enter long-
term remission, approximately one third of the patients show
treatment refractory epilepsy [5]. Thus, achieving seizure freedom
or a signiﬁcant reduction in seizure frequency, while avoidingunacceptable toxicities, represents the goal in the management of
epilepsy. Many patients can only achieve this goal with combina-
tion therapy [6]. However, the choice of AED combination partners
is often difﬁcult due to inacceptable toxicities caused by drug–drug
interactions, which in turn lead to dissatisfaction in the patients
and low adherence to therapy [7,8].
A favorable pharmacokinetic proﬁle of ZNS has been shown in
terms of low interaction potential with other AED, which facilitates
its use as an adjunctive therapy to achieve better seizure control.
Efﬁcacy and safety of ZNS have been extensively proven in
controlled clinical settings [10–14]. In addition, the ZADE
observational study showed good responder rates and health
related quality of life improvement after 4 months of ZNS
adjunctive treatment in clinical practice settings in Germany
and Austria [17]. The aim of the present observational study ZOOM
was to gather further real world data on ZNS-dosing, retention of
treatment, efﬁcacy, health-related quality of life under treatment,
as well as tolerability over a period of 6 months, with ZNS given as
add-on to a current AED monotherapy.
The majority (82.8%) of patients retained ZNS adjunctive
treatment for at least 6 months (Fig. 3A), and the majority of
these patients (96.1%) stated at the last visit that they would wish
to continue ZNS treatment beyond the study period. These ﬁndings
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with the treatment outcome. The retention rate is higher than
reported in the literature [18], where 24-week retention of less
than 70% was seen. The majority of patients reached their
respective target dose within a month, most of them within
2 titration steps. The median daily dose after titration was
200 mg, which was lower than in previous studies [10,17]. This
might indicate that the here observed population was less
severely ill and therefore required lower doses of ZNS than the
patients included in controlled clinical trials with ZNS [11–14].
The relatively short duration of epilepsy, the lower baseline
seizure frequency (Table 1 and Fig. 1), and the fact that patients
were to be on AED monotherapy at baseline, further corroborates
this assumption.
Within ZOOM, only 18.3% of the patients required dose changes
after titration with almost equal distribution of dose increases
(47.1%) and reductions (52.9%). Altogether, these ﬁndings indicate
that adjunctive therapy with ZNS is easy to initiate, maintain and
individualize in daily clinical practice.
Assessments of reported efﬁcacy revealed that the majority of
patients fulﬁlled the deﬁnition of response (reduction of seizure
frequency by 50%) already after 3 months of adjunctive
treatment with ZNS, and at 6 months, responder rate was as high
as 79.7% (Fig. 4). In addition, a fair amount (43.6%) of patients
reported seizure freedom after 6 months, thus indicating a
favorable outcome of ZNS treatment. The low sample size and
the observational non-comparative nature of the study do not
allow further conclusions regarding efﬁcacy. Nonetheless, the
ﬁndings are consistent with those from the ZADE non-interven-
tional study [17], where almost identical seizure outcome rates
were reported after 4 months of ZNS adjunctive therapy.
Correspondingly, the physicians’ assessment of overall seizure
outcome after 6 months was good or very good in more than 75% of
the patients within the present observational study ZOOM. Quality
of life assessed by means of the QOLIE-10 questionnaire improved
after 6 months of ZNS adjunctive treatment in mean by 22.2%
(27.7%, SD). In line with previous ﬁndings [19], subgroup analysis
according to the seizure-outcome after 6 months showed that
patients who became seizure free during the study reported a
signiﬁcant improvement in QoL, which could not be observed in
patients whose seizure frequency was not reduced by at least 50%
(Fig. 5). Importantly, for these non-responders, stable QoL scores in
the course of the study indicate that ZNS treatment did not negatively
affect quality of life
Previous studies have shown a negative impact of drug-
refractoriness of epilepsy on effectiveness of antiepileptic treat-
ment regimens [6,16]. Schiller and Najjar used the number of
previously discontinued AED regimens for classifying the stage of
drug-refractoriness of the disease. They observed that patients
with more discontinued (i.e. inefﬁcient) treatment regimens for
epilepsy were less likely to achieve seizure freedom or meaningful
seizure frequency reduction with a novel AED regimen [16]. A
subgrouping-approach was used in the present study as well,
where patients were classiﬁed for drug-refractoriness of epilepsy
according to the number of discontinued AED regimens over the
period of 5 years prior to inclusion. These subgroups did not
display any major differences of their retention rates at 6 months.
However, indeed patients with 3 or more previously discontinued
AEDs showed the lowest responder rate at 6 months, while
patients without any previous AED regimen showed the highest
(66.7 vs. 87.5% respectively). This conﬁrms previous studies, which
reported a strong negative correlation between the chance for
seizure freedom under a given AED and the number of AED tried in
the past [16].
In order to assess if AED medication at baseline potentially
affected outcome, subgroup analyses by baseline AEDs wereperformed. Four major subgroups according to concomitant AED
medication at baseline were identiﬁable within the ZOOM NIS
population: carboxamide derivatives, levetiracetam, lamotrigine,
and valproate. Retention rates were high within all groups, with
patients receiving levetiracetam or valproate having the lowest
(78.6% and 78.9% respectively), and carboxamide derivatives or
lamotrigine (88.0% and 92.9%, respectively) displaying the highest
(Fig. 3B). Although the low number of patients in each subgroup
prohibits conclusions, it seems noteworthy that the concomitant
AED treatment also seemed to be associated with variations in
efﬁcacy in terms of responder rate at 6 months, with the proportion
of responders ranging from 66.7% in the valproate group to 91.7% in
the lamotrigine group. In addition, the choice of baseline AED
seemed to be inﬂuenced by the patients’ age, with a considerably
higher amount of patients taking levetiracetam as a combination
partner of ZNS in the group of patients older than 60 years (45.8%),
as compared to patients 60 years or younger (27.5%) (Fig. 2). This
ﬁnding somewhat contrasts with previous observations [20],
where levetiracetam was preferably prescribed to younger
patients, and once again might reﬂect the poor sample size in
the present study. Nonetheless, these ﬁndings may deserve
attention as they might hint towards a differential beneﬁt of
ZNS as adjunctive therapy according to the choice of AED
combination partner, but also that this choice might be affected
by the patients’ age in a real-world setting. In this context, the
relatively high proportion of patients older than 60 years within
the present study also deserves attention; the fact that the mean
duration since diagnosis of epilepsy was lower in these patients
compared to the younger group points towards a relatively
higher proportion of patients with late-onset epilepsy in the
present study. For patients in this older subgroup, mean ZNS
dosing post-titration was lower than for the younger patients
(185.3  47.7 vs. 229.2  111.0 mg/d), while retention rate,
reported efﬁcacy and improvement of QoL were relatively higher.
These ﬁndings underline the importance of observational studies
with less stringent inclusion criteria regarding the patients’ age,
and might hint towards age-dependent therapeutic criteria in
everyday clinical practice.
The evaluation of tolerability for ZNS as only add-on therapy
within ZOOM was overall positive. It was rated good or very good by
the physicians in 94.0% of the patients. Patients were withdrawn
from the study due to an adverse event only in 3 cases, and due to
lack of efﬁcacy in 5. The majority of the reported adverse events
were non-serious, yet mostly considered related to ZNS treatment.
Importantly, the rates of adverse events considered related to ZNS
treatment seemed independent of the drug class of concomitant
AED medication. As in previous studies [10], fatigue, headache,
dizziness and sleep disorders were among the most frequently
reported adverse events.
The major limitation of the presents study was, that due to slow
recruiting, only 100 patients could be included. Thus, the
generalisability of the obtained results, while promising, is limited
due to the low sample size of 93 evaluable patients.
5. Conclusion
Taken together, the results of the present observational study
ZOOM are in accordance with previous ﬁndings that ZNS may be
efﬁcacious and well tolerated as adjunctive therapy in patients
with partial-onset seizures poorly controlled with AED mono-
therapy. The present data also hints at beneﬁcial effects of ZNS
adjunctive therapy on QoL, and may thus further strengthen the
role of adjunctive ZNS therapy. Further, due to its low interaction
proﬁle, ZNS appears to be easily combinable with a broad spectrum
of AEDs currently used for management of POS, thus representing a
useful therapeutic option in everyday clinical use.
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